Boston Scientific Corp (BSX)vsDelcath Systems Inc (DCTH)
BSX
Boston Scientific Corp
$46.66
-3.11%
HEALTHCARE · Cap: $74.53B
DCTH
Delcath Systems Inc
$16.39
-0.06%
HEALTHCARE · Cap: $585.02M
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 21904% more annual revenue ($21.00B vs $95.42M). BSX leads profitability with a 17.5% profit margin vs 0.6%. BSX appears more attractively valued with a PEG of 0.75. BSX earns a higher WallStSmart Score of 70/100 (B-).
BSX
Strong Buy70
out of 100
Grade: B-
DCTH
Hold41
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-27.6%
Fair Value
$39.07
Current Price
$46.66
$7.59 premium
Intrinsic value data unavailable for DCTH.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 22.9%
Generating 1.3B in free cash flow
Conservative balance sheet, low leverage
Revenue surging 20.6% year-over-year
Areas to Watch
Distress zone — elevated risk
Expensive relative to growth rate
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.4% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on Market Cap, PEG Ratio, Price/Book. Profitability is solid with margins at 17.5% and operating margin at 22.9%. PEG of 0.75 suggests the stock is reasonably priced for its growth.
Bull Case : DCTH
The strongest argument for DCTH centers on Debt/Equity, Revenue Growth. Revenue growth of 20.6% demonstrates continued momentum.
Bear Case : BSX
The primary concerns for BSX are Altman Z-Score.
Bear Case : DCTH
The primary concerns for DCTH are PEG Ratio, EPS Growth, Market Cap. A P/E of 1686.0x leaves little room for execution misses. Thin 0.6% margins leave little buffer for downturns.
Key Dynamics to Monitor
BSX profiles as a mature stock while DCTH is a growth play — different risk/reward profiles.
BSX carries more volatility with a beta of 0.57 — expect wider price swings.
DCTH is growing revenue faster at 20.6% — sustainability is the question.
BSX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
BSX scores higher overall (70/100 vs 41/100), backed by strong 17.5% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Delcath Systems Inc
HEALTHCARE · MEDICAL DEVICES · USA
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company is headquartered in New York, New York.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?